CTOs on the Move

PTC Therapeutics

www.ptcbio.com

 
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC`s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.ptcbio.com
  • 100 Corporate Court
    South Plainfield, NJ USA 07080
  • Phone: 908.222.7000

Executives

Name Title Contact Details
Giovanni Sosa
 Director Security Architect Profile
Marcio Souza
 Chief Operating Officer Profile
Benjamin Zaborenko
 Senior Director, IT Security Profile

Funding

PTC Therapeutics raised $125M on 08/12/2015

Similar Companies

Cancog Technologies

Cancog Technologies is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canadian Light Source

Canadian Light Source is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Center for Functional Genomics

Center for Functional Genomics is a Rensselaer, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alpine Biomed

Alpine Biomed is a Fountain Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerus

Cerus Corporation is dedicated solely to safeguarding the world`s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.